Sugi Predict

Sugi Predict / Compounds / SCHEMBL126109

SCHEMBL126109

SCHEMBL126109

C[CH]c1cc2c(cc1[N+](=O)[O-])OCO2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.57
▸ ALDH1A1 P00352 11/20 0.57
▸ MEN1 O00255 6/20 0.57
▸ KMT2A Q03164 6/20 0.57
▸ KDM4E B2RXH2 5/20 0.57
▸ POLB P06746 4/20 0.57
▸ GAA P10253 4/20 0.57
▸ L3MBTL1 Q9Y468 3/20 0.57
▸ MCL1 Q07820 1/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ CYP2D6 P10635 1/20 0.57
▸ CYP2C9 P11712 1/20 0.57
▸ CYP2C19 P33261 1/20 0.57
▸ THRB P10828 1/20 0.54
▸ ALOX12 P18054 1/20 0.54
▸ BLM P54132 1/20 0.54
▸ APAF1 O14727 1/20 0.53
▸ HK1 P19367 1/20 0.53
▸ DNMT1 P26358 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20739004 0.87 MAPT (0.55) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL30460431 0.84 MAPT (0.59) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL1425992 0.84 MAPT (0.59) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL718255 0.81 MAPT (0.74) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL20722838 0.80 MAPT (0.62) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL20723034 0.80 MAPT (0.62) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL11835722 0.80 ALDH1A1 (0.51) MAPTALDH1A1MEN1KMT2AKDM4E
Ammonia Solution, Strong SCHEMBL11877252 0.78 MAPT (0.52) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL15579441 0.77 MAPT (0.52) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL15579443 0.77 MAPT (0.52) MAPTALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040146863-A1 ELECTRONIC DETECTION OF BIOLOGICAL MOLECULES USING THIN LAYERS BRIDGER TECHNOLOGIES, INC. 2004-07-29 — — US claimed
US-5744101-A Photolabile nucleoside protecting groups AFFYMAX TECHNOLOGIES N.V. (GB) 1998-04-28 — — US claimed
EP-4367127-A1 CAP ANALOG FOR THE 5'-END OF EUKARYOTIC MESSENGER RNAS Westfälische Wilhelms-Universität Münster (DE) 2024-05-15 — — EP disclosed
US-20240033362-A1 LIPID COMPOSITION FOR THE DELIVERY OF THERAPEUTIC CARGOS NAT TECH & ENG SOLUTIONS SANDIA LLC (US) 2024-02-01 — — US disclosed
US-11554369-B2 Microfluidic package and method of making the same NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) 2023-01-17 — — US disclosed
WO-2023280934-A1 CAP ANALOG FOR THE 5'-END OF EUKARYOTIC MESSENGER RNAS WESTFÄLISCHE WILHELMS-UNIVERSITÄT (DE) 2023-01-12 — — WO disclosed
EP-4116313-A1 CAP ANALOG FOR THE 5'-END OF EUKARYOTIC MESSENGER RNAS Westfälische Wilhelms-Universität Münster (DE) 2023-01-11 — — EP disclosed
US-10933027-B1 Expanded pore particles and delivery methods thereof NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) 2021-03-02 — — US disclosed
US-20200316596-A1 MICROFLUIDIC PACKAGE AND METHOD OF MAKING THE SAME NAT TECH & ENG SOLUTIONS SANDIA LLC (US) 2020-10-08 — — US disclosed
US-10717079-B2 Microfluidic package and method of making the same NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) 2020-07-21 — — US disclosed
US-20190255503-A1 SILANE MIXTURES AFFYMETRIX, INC. 2019-08-22 — — US disclosed
US-5889165-A Photolabile nucleoside protecting groups AFFYMETRIX, INC. (US) 1999-03-30 — — US disclosed
US-5753788-A Photolabile nucleoside protecting groups AFFYMETRIX, INC. (US) 1998-05-19 — — US disclosed
US-5744101-A Photolabile nucleoside protecting groups AFFYMAX TECHNOLOGIES N.V. (GB) 1998-04-28 — — US disclosed
US-5744305-A Arrays of materials attached to a substrate AFFYMETRIX, INC. (US) 1998-04-28 — — US disclosed
US-5489678-A 6-NITRO-1,3-BENZOXAZOL-5-YL ALKYLOXY PROTECTIVE GROUP ON THE 5' POSITION OF A DEOXYNUCLEOSIDE; COMPUTERIZED SOLID PHASE SYNTHESIS AFFYMAX TECHNOLOGIES N.V. (NL) 1996-02-06 — — US disclosed
US-5424186-A Biosynthesis of oligonucleotides on solid substrate by irradiation of predefined segments to remove blocking agents; then coupling with nucleotide AFFYMAX TECHNOLOGIES N.V. (AN) 1995-06-13 — — US disclosed
EP-0562025-A4 — — 1994-03-30 — — EP disclosed
EP-0562025-A1 VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS AFFYMAX TECHNOLOGIES N.V. (AN) 1993-09-29 — — EP disclosed
WO-1992010092-A1 VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS AFFYMAX TECHNOLOGIES N.V. (AN) 1992-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10933027-B1 Expanded pore particles and delivery methods thereof NPC1L1, NPC1, NUP210 MAPT 3940/4885ALDH1A1 4526/4885MEN1 2278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.